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Whether routine screening for depression among nonpreg-
nant women of reproductive age improves identification 
and treatment of the disorder remains unclear. We con-
ducted a systematic review of the literature to address 5 
key questions specific to this population: 1) What are the 
current national clinical practice recommendations and 
guidelines for depression screening; 2) What are the preva-
lence and predictors of screening; 3) How well do screening 
tools detect depression; 4) Does screening lead to diagno-
sis, treatment, and improved outcomes; and 5) What are 
the most effective treatment methods?
Methods
We searched bibliographic databases for full-length arti-
cles published in English between 1990 and 2010 that 
addressed at least 1 of our key questions. 
Results
We identified 5 clinical practice guidelines pertinent 
to question 1, and 12 systematic reviews or post-hoc 
analyses of pooled data that addressed questions 3 through 
5. No systematic reviews addressed question 2; however, 
we identified 4 individual studies addressing this ques-
tion. Current guidelines do not recommend universal 
screening for depression in adults, unless staff supports 
are in place to diagnose, treat, and follow up patients. 
Reported screening rates ranged from 33% to 84% among 
women. Several validated screening tools for depression 
exist; however, their performance among this popula-
tion is unknown. Screening in high-risk populations may 
improve the patient’s receipt of diagnosis and treatment. 
Effective treatments include exercise, psychotherapy, and 
pharmacotherapy.
Conclusion
More research is needed on whether routine screening for 
depression among women of reproductive age increases 
diagnosis and treatment of depression, improves precon-
ception health, and reduces adverse outcomes.
Introduction
Approximately 14.8 million US adults (6.7%) experience 
major depression in a given year (1), and women are 1.7 
times as likely to experience depression as men (2). The 
12-month prevalence of major depressive disorder, 1 form 
of clinical depression, for nonpregnant women aged 18 to 
50 ranges from 8% to 16% (2,3) and may be highest among 
low-income women, for whom prevalence of depression 
(defined as minor depression/dysthymia or major depres-
sion) is estimated at 29% (4). Yet, only half of women with 
depression have ever received a clinical diagnosis of the 
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disorder (4), which is the first step toward treatment and 
recovery. Major depression is the leading cause of disabil-
ity in the United States for adults aged 15 to 44 (5) and 
is associated with diabetes (6), stroke, and coronary heart 
disease (7). Depression affects a woman’s preconception 
health (8); depression during pregnancy may affect preg-
nancy outcomes, such as preterm delivery and low birth 
weight (9-11) and may adversely affect the child’s intel-
lectual development, behavior, and mental health (12). 
In 1 study among women enrolled in Kaiser Permanente 
Northwest, approximately half of women with clinically 
diagnosed perinatal depression experienced depression in 
the 39 weeks before pregnancy (13), highlighting the need 
for identification and treatment of depression among non-
pregnant women of reproductive age.
Nonpsychiatric clinicians have difficulty recognizing 
depression in their patients (14,15). One meta-analysis 
found that nonpsychiatric clinicians accurately diagnosed 
depression in only 36% of depressed patients; another 
meta-analysis found a rate of 47% (14,15). However, it 
remains unclear whether routine screening for depression 
among nonpregnant women of reproductive age, defined 
as aged 15 to 44 years, improves identification, increases 
treatment rates, and leads to better overall and precon-
ception health. To consolidate current knowledge in this 
area, we conducted a systematic review of the literature to 
address 5 key questions specific to this group of women: 1) 
What are the current national clinical practice recommen-
dations and guidelines for depression screening; 2) What 
are the prevalence and predictors of screening; 3) How well 
do screening tools detect depression; 4) Does screening 
lead to diagnosis, treatment, and improved outcomes; and 
5) What are the most effective treatment methods?
Methods
Data sources
We searched the following electronic bibliographic 
databases: PubMed/MEDLINE (www.ncbi.nlm.nih.gov/
pubmed/), PsycINFO (www.apa.org/pubs/databases/psy-
cinfo/index.aspx), the Cochrane Database of Systematic 
Reviews (Cochrane Reviews) (www2.cochrane.org/
reviews/); and the National Guideline Clearinghouse 
(http://www.guideline.gov/). We used a combination of 
free-text terms and terms from the National Library of 
Medicine’s Medical Subject Headings (MeSH) (www.nlm.
nih.gov/mesh/). We conducted 3 separate searches focused 
on the following: 1) screening guidelines, 2) screening for 
depression in nonpregnant women of reproductive age, 
and 3) treatment for depression. We limited searches to 
English-language articles published between January 
1, 1990, and December 1, 2010, that described studies 
enrolling human participants. Free-text terms included 
those related to screening and treatment of depression, 
population-based surveys, and study types (Appendix). 
We supplemented searches of bibliographic databases 
by reviewing reference lists of retrieved articles and by 
searching reports, studies, articles, and monographs 
produced by federal and local government agencies, pri-
vate organizations, and educational organizations. For 
searches of articles, we used a 2-stage approach. We first 
searched for systematic reviews, defined as articles that 
synthesized relevant data from a number of independent 
studies and included well-defined, comprehensive search 
strategies, and then for individual studies, defined as re-
search studies involving human subjects that were not 
meta-analyses or systematic reviews.
Study selection
We developed inclusion criteria for each question a priori 
(Table 1). We conducted searches between March and 
December 2010. 
For question 1, we initially identified depression screening 
guidelines from 190 national organizations. After a review 
of summaries of the guidelines, we deemed 21 relevant 
and reviewed them fully. Of these, we excluded 16 because 
they were not from US-based organizations or because the 
guidelines did not focus primarily on depression. 
For study questions 2 through 5, an initial search of sys-
tematic reviews, meta-analyses, and post hoc analyses 
of pooled data found 5,200 mentions of depression. From 
this initial search, we categorized these mentions by each 
study question. We reviewed some studies for more than 
1 study question. The reasons for exclusion were that a 
separate synthesis of women was not reported (n = 186); 
the study was not a systematic review, meta-analysis or 
post-hoc analysis of pooled data (n = 43); or the study did 
not address our study question (n = 105). For questions 
2 through 5, the initial searches found 2,337 potential 
individual studies. We reviewed 334 individual studies 
and excluded 330 because they did not address our study 
questions. Therefore, we include a total of 12 systematic 
reviews, meta-analyses, or post-hoc analyses of pooled data 
and 4 individual studies that met our inclusion criteria for 
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questions 2 through 5. Below, we summarize specific stud-
ies included in each key question. 
For question 5, we limited nonpharmacotherapy treat-
ments to treatments described by the greatest number of 
systematic reviews identified: exercise and psychotherapy. 
We also limited pharmacotherapy to the 2 most common 
types, selective serotonin reuptake inhibitors (SSRIs) and 
selective norepinephrine reuptake inhibitors (SNRIs). For 
pharmacotherapy, we included only studies published 
from January 1, 2000, through December 1, 2010, because 
medications change over time, recent studies are most 
relevant, and systematic reviews offer a succinct summary 
measure of effectiveness.
Data extraction
Data extracted from the selected studies included study 
populations, outcomes and covariates, and results. For 
all study questions, at least 2 authors reviewed and dis-
cussed each article until both authors concurred on its 
inclusion.
Results
We identified recommendations and guidelines from 5 
national groups to answer question 1, and we identified 16 
studies that met our final review criteria for questions 2 
through 5. For question 2, we found 4 individual studies; 
for question 3, 1 meta-analysis; for question 4, 2 meta-
analyses and 1 systematic review; and for question 5, 5 
meta-analyses and 3 post-hoc analyses of pooled data.
Question 1. What are the current national clini-
cal practice recommendations and guidelines for 
depression screening? 
We identified recommendations and guidelines from 5 
national groups for screening adults for depression (16-
20); however, none provided specific guidance for non-
pregnant women of reproductive age (Table 2). The 
US Preventive Services Task Force (USPSTF) recom-
mends that providers screen adults for depression only 
when staff-assisted depression care supports are in place 
to ensure accurate diagnosis, effective treatment, and 
follow-up (17). The USPSTF defines “staff-assisted care 
supports” as clinical staff who assist the primary care clini-
cian by providing some direct depression care or coordina-
tion, case management, or mental health treatment. The 
American Academy of Family Physicians follows USPSTF 
guidelines for screening all adult patients for depression, 
using the clinician’s choice of screening method (19). The 
US Department of Veterans Affairs (VA) recommends 
annual depression screening for adult patients in primary 
care but notes the USPSTF recommendation of screen-
ing only when staff-assisted supports are in place (18). 
The American College of Obstetricians and Gynecologists 
(ACOG) does not advocate for or against screening for 
depression during well-woman care, but states that when 
clinicians identify a woman with depression, they must 
provide follow-up care if they do not refer her for care else-
where (16). The American Academy of Pediatrics (AAP) 
recommends screening mothers for depression at the 1-, 2-, 
4- and 6-month well-child visits and beyond the postpar-
tum period (20). The American Psychiatric Association has 
no published guidelines specific to depression screening, 
but in its guidelines on treatment for major depressive dis-
order, it acknowledges that primary care physicians, obste-
tricians, and physicians of other disciplines may screen for 
depression and initiate treatment for patients (21). The 
USPSTF, VA, ACOG, and AAP mention the 2-item Patient 
Health Questionnaire (PHQ-2), as an example of a short, 
standardized screener for depression.
Question 2. What are the prevalence and predictors 
of screening? 
We did not find any studies that assessed prevalence and 
predictors among nonpregnant women of reproductive age 
only. Four individual studies reported on prevalence rates 
of screening for depression among adult women of any age 
in primary care settings (22,23) or by providers serving 
women of reproductive age in obstetric practices (24,25). 
Desai et al evaluated the VA experience in implement-
ing universal screening, using a validated instrument, 
for depression (22). This study included 21,000 people 
receiving care at VA facilities across the United States 
in 2002. More than 84% of women of any age and almost 
80% of women and men aged 45 or younger were screened 
for depression. Among patients of all ages, no difference 
was found in screening rates between women and men, 
but patients were less likely to be screened if they were 
younger, unmarried, had greater service disability, or had 
medical comorbidity. 
Tudiver et al examined screening rates for 615 adult 
women aged 21 to 89 years accessing primary care in 2003 
at 19 rural health clinics in the United States (23). Rates 
of screening were low; 2.4% of visits documented formal 
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screening (ie, through use of a validated instrument), and 
33.2% of visits documented informal screening (ie, depres-
sion questions noted without mention of a screening tool).
Two studies examined the prevalence of screening for 
depression among obstetrician-gynecologists (OB/GYNs) 
(24,25). LaRocco-Cockburn et al surveyed practicing OB/
GYNs in Washington State in 2001 (25). Of the 282 (56%) 
who returned the survey, 44% reported often or always 
screening for depression in patients, 41% reported screen-
ing sometimes, and 15% reported never screening for 
depression regardless of signs or symptoms. In this study, 
81% of OB/GYNs used their own questions about mood or 
mental health, 32% used a validated screening tool (spe-
cific tool not reported), 16% used a validated patient self-
report paper-and-pencil test, and 7% used a structured 
clinical interview.
Dietrich et al conducted a cross-sectional survey among 
437 randomly selected US OB/GYNs (response rate, 58.3%) 
who had completed residency training in the previous 5 
years and currently provided care (24). Approximately 
40% of recent graduates and 50% of residents reported 
that depression was included on their practice encounter 
form. Only 9% to 12% reported routinely asking about 
depression or using a screening questionnaire to identify 
major or minor depression. The most common reasons 
for recognition of depression by OB/GYNs were that the 
patient appeared distressed (38%), presented with a symp-
tom (34%), or introduced the topic directly (26%).
Question 3. How well do screening tools detect 
depression?
We did not find any studies that assessed performance of 
depression screening tools among nonpregnant women of 
reproductive age only. Several short (1-2 questions) and 
longer (up to 30 questions) validated tools are available to 
screen for depression in primary care populations (26,27). 
The PHQ-2, which asks, “Over the past 2 weeks, how often 
have you been bothered by a) little interest or pleasure in 
doing things and b) feeling down, depressed, or hopeless,” 
may perform as well as longer tools (28) or could be used 
as an initial screen, with a longer screen administered 
to patients with affirmative answers to both questions 
(18). Depression-specific instruments may help clinicians 
recognize depression more easily than instruments that 
measure multiple mental health conditions (29). With any 
screening tool, a diagnostic interview is needed to confirm 
the presence of depression.
We found 1 meta-analysis of the performance of instru-
ments among adult men and women in primary care 
settings (30). It examined performance of case-finding 
instruments used for routine screening in primary care 
populations of men and women of all ages (30). This article 
evaluated only 21 of the 38 studies identified (because of 
study limitations); the 21 studies examined 16 validated 
case-finding instruments. For detecting major depression 
in a primary care population using routine screening with 
a validated case-finding tool, the median sensitivity was 
85% (range, 50%-97%), the median specificity was 74% 
(range, 51%-98%), and no statistically significant differenc-
es between instruments were found. The study concluded 
that several case-finding instruments are feasible to use in 
primary care settings and that the instruments perform 
sufficiently to facilitate identification of depression.
Question 4. Does screening lead to diagnosis, treat-
ment, and improved outcomes? 
We did not find any systematic reviews or individual 
studies that addressed this question among nonpreg-
nant women of reproductive age only. We found 2 meta- 
analyses (29,31) and 1 systematic review (32) that exam-
ined this question among the general population in pri-
mary care and hospital settings. Two studies (31,32) were 
conducted to inform and update USPSTF guidelines on 
screening for depression in adults. Pignone et al reviewed 
randomized trials published between January 1994 and 
August 2001 and included 14 studies in primary care 
settings that examined the effect of screening patients 
for depression on identification, treatment, and health 
outcomes (31). The included trials examined a range of 
screening intervention strategies, including feedback of 
screening scores, feedback and general education of provid-
ers, feedback and treatment advice, and integrated recog-
nition and management approaches with coordinated fol-
low-up of diagnosis and treatment. Screening resulted in a 
2- to 3-fold increase in clinicians’ recognition of depression. 
However, in a comparison of absolute differences in propor-
tions treated, the effect of screening on rates of treatment 
was mixed; 4 studies found positive effects and 5 studies 
found no effect. Increases in rates of treatment generally 
resulted in increases in prescriptions for antidepressants 
rather than referrals to mental health professionals. Three 
out of 7 studies included in the meta-analysis found signif-
icant improvement in depression between groups screened 
for depression and groups not screened. The meta-analysis 
found that patient and provider characteristics, use of par-
ticular outcome measures, follow-up time, or trial quality 
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did not explain the mixed findings; however, insufficient 
power may explain the results of some negative trials. A 
meta-analysis of the 7 studies showed that screening with 
or without further intervention was associated with a 13% 
(95% confidence interval [CI], 5%-21%) reduction in risk of 
remaining depressed. Additionally, variations in interven-
tions limited their interpretation of findings.
O’Connor et al (32) published an update to the study by 
Pignone et al. The update included studies published 
from January 1998 to December 2007 on randomized con-
trolled trials (RCTs) conducted in primary care settings 
among the general adult population. The authors found 2 
good-quality and 2 fair-quality RCTs not included in the 
study by Pignone et al. The updated review supported the 
original findings, that primary care depression screening 
may be effective when the treating physician works with 
other staff who provide part of the depression care, such 
as assessment and monitoring, or when extra efforts are 
made to enroll patients in mental health specialty care.
The study by Gilbody et al (29) examined the effect of 
screening using a standardized depression screening or 
outcome assessment instrument alone, without substan-
tial organizational enhancements (such as clinician edu-
cation, nurse case management, and integration between 
primary and secondary care), on recognition of depression 
and improvement in outcomes among nonpsychiatric 
patients in primary care and hospital settings. The study 
identified 16 RCTs comparing usual care with routine 
screening administered by research staff and feedback 
of results to clinicians. The RCTs did not report effects 
separately among women. Eleven of the 16 examined the 
effect of screening on the clinician’s recognition of depres-
sion. Seven of the 16 were conducted among the general 
population and found screening was not associated with 
increased likelihood of recognition of depression (relative 
risk [RR], 1.03, 95% CI, 0.85-1.24). In 4 trials conducted 
among high-risk populations, screening increased the 
likelihood of recognition of depression by 67%. Ten of 
the 16 studies examined the effect of depression screen-
ing on management of depression. Screening marginally 
increased the likelihood of the patient receiving any inter-
vention for depression (RR, 1.30, 95% CI, 0.97-1.76) with 
no difference between high-risk and general primary care 
populations.
In pooled data from 5 studies that examined the effect of 
screening on depression outcomes, the meta-analysis found 
no effect (standardized mean difference, −0.02; 95% CI, 
−0.25 to 0.20) (29). The authors conclude that use of screen-
ing instruments alone in unselected populations within 
primary care and hospital settings, without organizational 
enhancements, does not improve rates of depression treat-
ment or outcomes. They state that routine screening among 
high-risk populations may be more effective.
Question 5. What are the most effective treatment 
methods 
We found 5 meta-analyses and no individual studies that 
met the inclusion criteria for nonpharmacologic treatments 
and 3 post-hoc analyses of pooled data that examined the 
effectiveness and safety of SSRIs and SNRIs in women.
Three meta-analyses explored the association between 
exercise and depression and evaluated differences by sex 
(33-35) (Table 3). All found that exercise reduced mean 
depression scores (effect size [ES], 0.53-0.80) with no dif-
ference by sex. North et al (35) reviewed 80 studies of any 
design, 16 of which included women only. Exercise was 
defined as aerobic exercise and muscular strength-build-
ing. The overall ES was −0.53. Craft et al (33) included 
30 studies of any design, 4 that included women only and 
included aerobic and resistance exercise. They found a 
greater reduction in depression symptoms among subjects 
with more severe depression and those undergoing longer 
interventions.
In the third meta-analysis, Rethorst et al (34) reviewed 
58 published RCTs, 7 of which included women only, and 
evaluated moderate to vigorous exercise as a treatment 
for depression. Controls either received no treatment or 
were on a wait list for treatment. Exercise was found to 
be beneficial in studies of participants clinically diagnosed 
with depression (17 studies) and among participants not 
clinically diagnosed with depression (40 studies), although 
the ES was greater among clinically diagnosed samples 
(ES, −1.03 for clinically diagnosed and ES, −0.59 for not 
clinically diagnosed).
We found 2 meta-analyses (36,37) that evaluated different 
types of psychotherapy (cognitive therapy [CT], individual 
versus group psychotherapy, and short-term psychody-
namic psychotherapy) by sex (Table 3). Overall, the meta-
analyses consistently found psychotherapy more effec-
tive than no treatment. Robinson et al (37) analyzed 58 
studies published during 1976 through 1986, 29 of which 
focused on depression outcome measures. The combined 
sample was 80% female with an average age of 39.4 years. 
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Psychotherapy resulted in lower mean depression scores 
compared with no treatment (ES = 0.93). No differences 
were found by sex. Gloaguen et al (36) conducted a meta-
analysis of 48 RCTs to evaluate the effectiveness of CT for 
treatment of major depression or dysthymic disorder. They 
found that CT was more effective than antidepressants, 
and there were no differences by sex.
Three articles examined the effectiveness and safety of 
SSRIs and SNRIs in women, and all were post-hoc analy-
ses of pooled data (Table 3). Two studies examined the 
effect of SSRIs on level of depression (38, 39). Khan et al 
(39) found rates of response (65% vs 40%, P < .001) and 
remission (45% vs 14%, P < .001) greater for women tak-
ing SSRIs than placebo. Entsuah et al (38) found higher 
rates of depression absence (31% vs 20%) and remission 
(34% vs 24%) among women taking SSRIs compared with 
those taking placebo (P < .05). Among participants aged 
40 years or younger, differences in rates of remission and 
absence of depression between those taking SSRIs and 
those taking placebo did not reach statistical significance 
(38). Three studies examined the effects of different SNRIs 
on depression among women (38-40) and found greater 
response and remission rates among women taking SNRIs 
compared with those taking placebo (38-40).
Discussion
Our systematic review of the literature identified several 
gaps in knowledge of screening, detection, and treatment 
of depression among nonpregnant women of reproductive 
age. Current USPSTF screening guidelines do not recom-
mend universal screening for depression among adults 
unless staff supports are in place to diagnose, treat, and 
follow up patients (17). It is unclear what percentage of 
clinical practices serving nonpregnant women of reproduc-
tive age fit these criteria. The percentage of women who 
are screened and the percentage of providers who screen 
nonpregnant women for depression are largely unknown. 
The limited data available suggest low screening rates, 
although prevalence of depression is high. Several validat-
ed screening tools exist and perform equally well in prima-
ry care settings. However, we found no studies examining 
the performance of the screening tools specifically among 
nonpregnant women of reproductive age.
Additionally, no studies were found that examined the 
effect of depression screening on diagnosis, treatment, 
and outcomes specifically among nonpregnant women of 
reproductive age. Studies suggest that screening in high-
risk populations may be effective in clinician recognition of 
depression and patient receipt of treatment (29). Women 
of reproductive age may be considered high risk, especially 
low-income women attending public family planning and 
OB/GYN clinics, where, in 3 studies from different parts of 
the United States, 19% to 48% of women screened positive 
for moderate to severe or clinically relevant depression 
(41-43). Engaging low-income women in treatment can 
improve depressive symptoms; however, it takes consider-
able time and resources, and engagement is difficult to 
achieve, even when treatment is free and child care and 
transportation are provided (44).
Various treatment options exist for depressed women, 
including exercise, psychotherapy, and pharmacotherapy. 
In England, exercise is a first-line therapy (45), but not 
in the United States. All treatments reviewed performed 
better than placebo; however, treatment response rates 
were low. Further research is needed to identify whether 
combining treatments can further improve effectiveness.
In summary, although studies have documented high 
rates of depression among women of reproductive age and 
significant detrimental health effects for them and their 
families, how to engage women in effective treatment and 
how to create systems of affordable and acceptable care 
remain future challenges. Recent changes in health insur-
ance through national health care reform may provide 
insurance coverage for more people with mental illnesses. 
Monitoring access and use among women of reproductive 
age will help evaluate whether this policy improves men-
tal health in the United States.
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Tables
Table 1. Research Question, Inclusion Criteria, and Population Included,a Systematic Review of Articles on Depression Screening and 
Treatment Among Nonpregnant Women of Reproductive Age in the United States, 1990-2010 
Inclusion Criteria Population Included
Studies Meeting Inclusion 
Criteria (Type)
1. What are the current national clinical practice recommendations and guidelines for depression screening?b
Meets criteria for inclusion in the National Guideline Clearinghouse (http://
www.guideline.gov/about/inclusion-criteria.aspx) 
Additional requirements included:
• Was developed by a national organization.
• Provides detailed information about the methods used to search, collect, 
and select the evidence (either in the original guideline, or in an associated 
evidence review).
• Provides details about the methods used to assess the quality of the litera-
ture (eg, either rating or grading the literature that the recommendations 
are based on, providing evidence tables and detailed discussion of the 
underlying evidence).
• Makes clear recommendations.
• Includes the target population. Specific reference to the target population 
is not necessary to meet this inclusion criterion. For example, guidelines for  
the general adult populations would be included as they are assumed to be 
relevant to the target population (women of reproductive age who are not 
pregnant).
Adult men and women  (guidelines)
2. What are the prevalence and predictors of screening?
Describes a study that screened patients for depression or a survey of clini-
cians’ reports or medical record review of screening for depression.
Adult women and women seen by 
obstetrician/gynecologists
 (individual studies)
3. How well do screening tools detect depression?b
Describes a validated screening tool for depression in adult primary care popu-
lations.
Adult men and women 1 (meta-analysis)
4. Does screening lead to diagnosis, treatment, and improved outcomes?b
Presents data related to the rates of depression diagnosis and treatment 
among patients screened for depression compared with patients not screened.
Adult men and women  (2 meta-analyses, 1 systematic 
review)
5. What are the most effective treatment methods?
Examines the effect of exercise, psychotherapy, SSRI, or SNRIc on depression. Adult men and women from the 
general population with results 
presented separately for women, 
or gender evaluated as an effect 
modifier
8 ( meta-analyses,   post-hoc 
analyses of pooled data)
 
Abbreviations: SSRI, selective serotonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor. 
a All studies and reports were full-length articles published in the English language, between 10 and 2010. 
b Given the lack of studies reporting data separately for women, articles for the general US population were included. 
c Articles on SSRIs and SNRIs were limited to those published between 2000 and 2010.
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Table 2. National Guidelines and Recommended Screening Tools for Depression Screening in Adults, 2010
Organization, Year Recommendation Screening Tool
US Preventive Services Task 
Force, 200 (1)
Screen adults for depression when staff-assisted depression care 
supports are in place to ensure accurate diagnosis, effective treat-
ment, and follow-up. 
Do not routinely screen adults when staff-assisted care supports 
are not in place. There may be considerations to support screen-
ing in an individual patient.
Several screening tools exist. Insufficient evi-
dence to support 1 method over another.
American Academy of Family 
Physicians, 2010 (1)
Screen adults for depression only when staff-assisted depression 
care supports are in place to ensure accurate diagnosis, effective 
treatment, and follow-up. 
Recommends against routinely screening adults for depression 
when staff-assisted depression care supports are not place. There 
may be considerations that support screening for depression in 
an individual patient.
Clinicians may choose the method that best fits 
their personal preference, the patient population 
served, and the practice setting.
US Department of Veterans 
Affairs, 200 (18)
Annual screening of adult patients seen in primary care. Screen using a standardized tool such as the 
PHQ-2. Use PHQ- as an aid for diagnosis, mea-
surement of symptom severity, and to assess 
treatment response.
American College of Obstetricians 
and Gynecologists, 200 (16)
Does not advocate for or against routine screening. Screening 
can consist of a written questionnaire, or clinician may ask if 
other symptoms are present. Clinicians should provide follow-up 
care for women identified with depression or refer elsewhere for 
care. Referral is recommended for women with depression with 
suicide risk or psychotic symptoms, those with bipolar disorder, 
depressed adolescents, patients who fail to respond to treatment, 
substance abusers, or if clinician is not comfortable treating 
patient.
Suggests PHQ-2 as an example of one of many 
valid screening tools.
American Academy of Pediatrics, 
2010 (20)
Recommends screening mothers for depression at the 1-, 2-, -, 
and 6-month well-child visits and beyond the postpartum period. 
Based on the severity of the depression score, pediatricians 
should provide reassurance, supportive strategies, and referral for 
specific interventions.
Edinburgh Postnatal Depression Scale for post-
partum depression and PHQ-2 to assess depres-
sion outside of the postpartum period.
 
Abbreviations: PHQ-2, Patient Health Questionnaire, 2-question version; PHQ-, Patient Health Questionnaire, -question version.
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Authors, year North et al, 10 ()
Type of analysis Meta-analysis
Studies included: design(s); total 
number/number women only; years 
studies published
RCT, non-RCT comparative, 1 group pre-post, matching groups, convenience sample groups, and pre-test/post-test 
studies with any measure of depression as dependent variable; 80/16; English language; published or scheduled for 
publication on or before June 1, 18.
Population of interest and exclusion 
criteria
Studies of any reported depression including mood disorders, psychogeneous or endogenous types of depression, 
primary or secondary
Outcome, intervention, comparison 
group, and covariates
Outcome: Level of depression; intervention: aerobic and resistance exercise; comparison groups: no treatment, 
wait-list, psychotherapy, enjoyable activity, relaxation, less exercise, anaerobic exercise, exercise and psychotherapy; 
covariates: source of subjects, group assignment, degree of internal validity, initial level of depression, age, sex, exer-
cise duration per episode, type, frequency and intensity, additional therapy, health status.
Results The overall ESa of exercise on depression was −0.53 ± 0.85. 
Significant main effects were found for source of subjects (medical/psychological patients > students/citizens); 
source of study (published > unpublished); purpose of exercise (medical rehabilitation > general health or psycho-
logical rehabilitation); health status (sicker > healthier); type of exercise (weight training > aerobic); duration (longer 
> shorter). No significant moderating effects found for group assignment, internal validity, sex, age, or depression 
diagnosis.
Limitations Included non-RCT studies and studies with depression as secondary diagnosis to another mental health condition.
Authors, year Craft and Landers, 18 ()
Type of analysis Meta-analysis
Studies included: design(s); total 
number/number women only; years 
studies published
RCT, non-RCT comparative and pretest/posttest studies with measure of depression as dependent variable; /; 
published or scheduled for publication on or before November 16.
Population of interest and exclusion 
criteria
2,18 people with depression as primary diagnosis or secondary diagnosis to another mental health condition; 
excludes studies on depression as a result of physical health problem.
Outcome, intervention, comparison 
group, and covariates
Outcome: level of depression; intervention: aerobic and resistance exercise; comparison groups: wait-list, group or 
individual therapy, behavioral interventions; covariates: initial level of depression; age; sex; exercise duration per epi-
sode, type, frequency, and intensity; additional therapy.
Results Compared with wait-list controls, people who exercised were ES 0.77 (95% CI, −1.08 to −0.47) less depressed than 
individuals on a wait list. Exercise was as beneficial as group/individual therapy and behavioral interventions. 
Significant main effects were found for initial level of depression (moderate to severe group > mild to moderate 
group); source of study (published > unpublished); primary versus secondary depression; no significant moderat-
ing effects were found for sex , age, or exercise type, duration, frequency, or intensity on the relationship between 
exercise and depression. Individuals who exercised 9–12 weeks were less depressed than those who exercised ≤8 
weeks.
Limitations Included non-RCT studies; included depression as secondary diagnosis to another mental health condition; limited 
generalizability because of exclusion criteria; measures of level of depression not stated.
Authors, year Rethorst et al, 200 ()
 
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective sero-
tonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global Impressions-
Severity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. 
a ES = standardized mean difference between intervention and control groups.
(Continued on next page)
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Treatment Description
Exercise (continued) 
Type of analysis Meta-analysis
Studies included design(s); total 
number/number women only; years 
studies published
RCTs only; 8/; 181-200.
Population of interest and exclusion 
criteria
2,82 people with depression ( clinical, 2,08 nonclinical); depression associated with physical or psychological 
illness excluded
Outcome, intervention, comparison 
group and covariates
Outcome: level of depression; intervention: moderate to vigorous aerobic or resistance exercise; comparison group: 
no treatment or wait list, secondary comparison groups: psychotherapy and antidepressant medication; covariates: 
depression type, intervention duration, exercise type, frequency, bout duration, sex, methodological characteristics, 
treatment adherence, dose response.
Results Overall ES of −0.80 indicates participants in the exercise treatment had significantly lower depression scores than 
controls. Exercise was more effective among clinically depressed participants (ES = −1.03) than nonclinical samples 
(ES = −0.59). Aerobic and resistance exercises were equally effective. No significant differences in the effect of exer-
cise compared with psychotherapy or antidepressant medication. No significant moderating effects found for sex on 
the relationship between exercise and depression.
Limitations Limited generalizability because of exclusion criteria.
Cognitive therapy
Authors, year Gloaguen et al, 18 (6)
Type of analysis Meta-analysis
Studies included: design(s); total 
number/number women only; years 
studies published
RCTs only; 8/; Published studies and those presented at international congresses, 1–16
Population of interest and exclusion 
criteria
2,6 people with major depression or mild/moderate dysthymia; excluded psychotic and bipolar disorder
Outcome, intervention, comparison 
group and covariates
Outcome: level of depression assessed by BDI; intervention: cognitive therapy; Comparison group: waiting list or pla-
cebo, antidepressant medication, behavioral therapy, other psychotherapeutic treatment (psychodynamic therapies, 
interpersonal therapies, nondirective, supportive, relaxation and alternative bibliotherapy); covariates: BDI scores, 
sex, age.
Results Cognitive therapy was significantly better than waiting-list or placebo (P <.001), antidepressants (P < .001), and a 
group of miscellaneous therapies (P <.001). No covariates modified effect size in multivariable analysis.
Limitations Limited to published articles and studies presented at international congresses. Limited generalizability because of 
exclusion criteria.
Psychotherap
Authors, year Robinson et al, 10 ()
Type of analysis Meta-analysis
 
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective sero-
tonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global Impressions-
Severity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. 
a ES = standardized mean difference between intervention and control groups.
Table 3. (continued) Meta-analyses and Post-hoc Analyses of Pooled Data Evaluating Effectiveness of Treatments for Depression 
Among Women of Reproductive Age
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Treatment Description
Psychotherapy (continued) 
Studies included design(s); total 
number/number women only; years 
studies published
Studies comparing treatment to no treatment or different types of therapy; excluded case histories and pre-post 
designs and treatments without a prominent verbal component, and marriage/family therapy; 8/unknown; Mean 
percentage of female clients per study was 80%; range: 0%–100%; psychological abstracts 16-186 and rel-
evant journals 18-186.
Population of interest and exclusion 
criteria
People with depression either meeting formal diagnostic criteria or screening positive; excluded subjects described 
in more general terms or by other specific diagnoses; studies examining inpatients or children and adolescents also 
excluded; mean age:  years, range: 1-1
Outcome, intervention, comparison 
group, and covariates
Outcome: depression symptoms; assessed by multiple different validated screeners for depression, general mental 
health and functioning; intervention: 1 of  types of therapies: 1) cognitive, 2) behavioral, ) cognitive-behavioral, ) 
general verbal,  mean weeks of treatment and 8. mean number of sessions; comparison: no treatment (n = 6 
studies), wait list (n = 2 studies), placebo (n =  studies); covariates: sex and age, weeks of treatment, number of 
sessions.
Results Psychotherapy was more effective than no treatment (ES = 0. at posttreatment and 0.68 at follow-up, average 1 
weeks after treatment) and wait list (ES = 0.8) (P < .0 for all). In the 2 studies using outcome measures specific 
to depression, psychotherapy was more effective than wait list (ES = 0., P < .0). No differences in effect sizes 
found by sex, age, weeks of treatment, or number of sessions.
Limitations Included non-RCTs; limited to published articles and abstracts presented at conferences.
SSRIs/SNRIs
Authors, year Entsuah et al, 2001 (8)
Type of analysis Post-hoc analysis of pooled data
Studies included design(s); total 
number/number women only; years 
studies published
Included placebo controlled double-blind, active-controlled phase 2,, or  trials; 8/0; 62%-6% of participants 
female, depending on intervention type; published or reported 12 to 18.
Population of interest and exclusion 
criteria
2,045 people meeting DSM-III or IV criteria for major depressive disorder and ≥20 on HAM-D-21 or 25 on 
Montgomery Asberg Depression Rating Scale; age range 18-8 years; inpatients (n = 6) and outpatients (n = 
1,); excluded pregnant, lactating; significant history of cardiovascular, renal, hepatic, or seizure disorders; 
abnormal physical examination or electrocardiogram; history of alcohol or drug abuse; use of investigational or anti-
psychotic drugs in last 0 days, monoamine oxidase inhibitors within 1 days, or antidepressants anxiolytics or seda-
tive-hypnotic drugs within  days.
Outcome, intervention, comparison 
group and covariates
Outcome: depression absence, response or remission to treatment, measured by score of 0 on depressed mood 
item of HAM-D-21; score ≤7 on HAM-D-17; and ≥50% decrease in score on HAM-D-21, respectively; intervention: ven-
laflaxine (n = 86); SSRI (n = ); 6-12 weeks; comparison group: placebo (n = 0); covariates: age, sex
 
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective sero-
tonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global Impressions-
Severity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. 
a ES = standardized mean difference between intervention and control groups.
Table 3. (continued) Meta-analyses and Post-hoc Analyses of Pooled Data Evaluating Effectiveness of Treatments for Depression 
Among Women of Reproductive Age
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Treatment Description
SSRIs/SNRIs (continued)
Results For both men and women, both venlaflaxine and SSRIs were significantly more effective in depression absence, 
response, and remission than placebo. At 8 weeks, rates of remission among women treated with venlaflaxine were 
higher (%) than those among people receiving SSRIs (%) or placebo (2%), P < .001. Rates of response with 
venlaflaxine (6%) were higher than placebo (%), P < .001. Rates of absence of depressed mood among women 
receiving venlaflaxine (%) or SSRI (1%) were higher than placebo (20%), P < .003. Among participants ≤40 years 
(men and women combined), rates of remission (P < .001) and absence of depression (P < .001) were higher with 
venlafaxine than placebo.  Differences between SSRIs and placebo were not statistically significant among partici-
pants ≤40 years. No effect of age or sex on effectiveness in depression absence, remission, or response to venlaflax-
ine or SSRIs.
Limitations Limited generalizability; disproportionately large number of patients treated with fluoxetine in SSRI group; no studies 
examined setraline or citalopram; no information on menopausal status.
Authors, year Khan et al, 2006 ()
Type of analysis Post-hoc analysis of pooled data.
Studies included design(s); total 
number/number women only; years 
studies published
Double-blind RCTs, phase 2, , and ; 1/0; conducted 16–200.
Population of interest and exclusion 
criteria
2 people with depression; 1 (%) women with depression; n = 80 on placebo; n = 1 on SSRI; n = 26 on 
SNRI; excluded people with severe illness, suicidal patients, and patients with concomitant disorders.
Outcome, intervention, comparison 
group and covariates
Outcome: level of depression assessed by response and remission rates from HAM-D-1 scores; intervention: SSRI 
(fluoxetine, paraxetine CR, sertaline, citalopram, excitalopram), SNRI (venlaflaxine ER); comparison group: placebo; 
covariates: baseline depression score and sex.
Results Response rates greater for women taking SSRIs (6.8%) and SNRIs (6.2%) than placebo (0%) (P < .001). 
Remission rates higher in women taking SSRIs (.1%) and SNRIs (6.2%), than placebo (1.8%) (P < .001). Women 
taking SSRIs had ES 0.82, and women taking SNRI had ES 0.6. Effect of SSRIs greater in women than men (P = 
.001). No difference between women and men taking SNRI.
Limitations Duration of medication use not stated; limited generalizability because of exclusion criteria.
Authors, year Kornstein et al, 2006 (0)
Type of analysis Post-hoc analysis of pooled data.
Studies included design(s); total 
number/number women only; years 
studies published
Randomized, multicenter, double-blind, placebo-controlled trials; /0; 2002-200.
Population of interest and exclusion 
criteria
N = 1622 people with major depressive disorder defined as HAM-D-1 score >1; 1,062 women n = 8 duloxetine; 
n = 8 placebo; mean age 1 years; excluded people with current and primary Axis I disorder other than depres-
sion, an Axis II disorder, lack of response to ≥2 courses of antidepressant therapy, serious medical illness, risk of 
suicide, history of substance abuse in last year, positive drug screen.
Outcome, intervention, comparison 
group and covariates
Outcome: level of depression; intervention: duloxetine (0, 60, 80, and 120 mg/day); comparison group: placebo; 
covariates: sex, study design characteristics, methodological characteristics, study duration (- weeks).
 
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective sero-
tonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global Impressions-
Severity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. 
a ES = standardized mean difference between intervention and control groups.
Table 3. (continued) Meta-analyses and Post-hoc Analyses of Pooled Data Evaluating Effectiveness of Treatments for Depression 
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Treatment Description
SSRIs/SNRIs (continued)
Results For women, duloxetine was more effective than placebo in HAM-D-1 (ES = 0.22, P <.001), CGIS (ES = 0.1, P 
<.001), and PGI-I (ES = 0.0, P <.001) measures. Significantly greater improvement in VAS pain scores in duloxetine-
treated compared with placebo-treated women.
Limitations Duration of treatment - weeks; menopausal status unknown; generalizability limited because of exclusion criteria.
 
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective sero-
tonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global Impressions-
Severity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. 
a ES = standardized mean difference between intervention and control groups.
 
Appendix. Free-Text Search Terms Related to Screening and Treatment of Depression, 
Population-Based Surveys, and Study Types Used in Electronic Searches
Abbreviations: NHANES, National Health and Nutrition Examination Survey; NHIS, National Health Interview Survey; BRFSS, Behavioral Risk Factor Surveillance 
System; MEPS, Medical Expenditure Panel survey; NAMCS, National Ambulatory Medical Care Survey. 
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